Alfonso J Rodriguez-Morales1, Jaime A Cardona-Ospina2, Valeria Ramirez-Jaramillo3, Javier A Gaviria4, Gloria María González-Moreno5, Juan D Castrillón-Spitia6, Alejandra López-Villegas7, Estefania Morales-Jiménez7, Valentina Ramírez-Zapata7, German Eduardo Rueda-Merchán7, Adriana M Trujillo3, Fredy A Tabares-Villa8, Valentina Henao-SanMartin3, David R Murillo-Garcia3, Johana Andrea Herrera-Soto9, Marta Liliana Buitrago-Cañas9, Matthew H Collins10, Juan Carlos Sepúlveda-Arias11, José J Londoño9, Héctor D Bedoya-Rendón9, Javier de Jesús Cárdenas-Pérez9, Sandra X Olaya12, Guillermo J Lagos-Grisales13. 1. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; Infection and Immunity Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Medical School, Faculty of Health Sciences, UniFranz, Cochabamba, Bolivia. Electronic address: arodriguezm@utp.edu.co. 2. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; Infection and Immunity Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. 3. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. 4. ESE Hospital Santa Mónica, Dosquebradas, Risaralda, Colombia. 5. Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; ESE Hospital Santa Mónica, Dosquebradas, Risaralda, Colombia. 6. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; Biomedicina, Fundación Universitaria Autónoma de Las Américas, Pereira, Risaralda, Colombia; ESE Hospital San Pedro y San Pablo, La Virginia, Risaralda, Colombia. 7. Biomedicina, Fundación Universitaria Autónoma de Las Américas, Pereira, Risaralda, Colombia. 8. Infection and Immunity Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. 9. ESE Hospital San Pedro y San Pablo, La Virginia, Risaralda, Colombia. 10. Emory University, Atlanta, GA, USA. 11. Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; Infection and Immunity Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. 12. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia; Critical Care Obstetrics & Gynecology, ESE Hospital Universitario San Jorge, Pereira, Risaralda, Colombia. 13. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia; Colombian Collaborative Network of Zika, Chikungunya and Other Arboviruses (RECOLZIKA), Pereira, Risaralda, Colombia.
Abstract
BACKGROUND: Zika virus (ZIKV) infection has emerged as a significant threat for pregnant women and newborns in populations living in or visiting Latin America. We previously reported a preliminary analysis in Sucre, Colombia, as the first group of pregnant women with RT-PCR-confirmed ZIKV (ZIKa enEmbarazadas yReciénNacidos enCOLombia, ZIKERNCOL). METHODS: In this second report, findings of the first 86 pregnant women from La Virginia and Dosquebradas (municipalities), Risaralda, Colombia, with RT-PCR-confirmed ZIKV infection are reported. Clinical, demographical and obstetrical findings are described. RESULTS: All women reported ZIKV symptoms during pregnancy: 79.1% rash, 55.8% fever, among others. In addition to ZIKV, RT-PCR was positive for dengue in 18.6%; 45.3% Dengue IgM+; 5.8% RT-PCR positive for chikungunya; 3.6% Chikungunya IgM+. STORCH screening in mother: 11.6% IgG + anti-Toxoplasma gondii, 6% IgG + anti-rubella, 4.7% IgG + CMV. The rest of STORCH tests were negative. Microcephaly was observed in 2.4% of the newborns. No calcifications or other CNS alterations were detected. One newborn had cleft palate and one had bilateral renal ectopy. CONCLUSIONS: The rate of microcephaly in our cohort was consistent with other studies. Pregnant women in endemic areas should be followed and tested according to standard protocols, and asymptomatic ZIKV infection should be considered. Long-term follow-up of children is required in the congenital Zika syndrome (CZS) assessment.
BACKGROUND:Zika virus (ZIKV) infection has emerged as a significant threat for pregnant women and newborns in populations living in or visiting Latin America. We previously reported a preliminary analysis in Sucre, Colombia, as the first group of pregnant women with RT-PCR-confirmed ZIKV (ZIKa enEmbarazadas yReciénNacidos enCOLombia, ZIKERNCOL). METHODS: In this second report, findings of the first 86 pregnant women from La Virginia and Dosquebradas (municipalities), Risaralda, Colombia, with RT-PCR-confirmed ZIKV infection are reported. Clinical, demographical and obstetrical findings are described. RESULTS: All women reported ZIKV symptoms during pregnancy: 79.1% rash, 55.8% fever, among others. In addition to ZIKV, RT-PCR was positive for dengue in 18.6%; 45.3% Dengue IgM+; 5.8% RT-PCR positive for chikungunya; 3.6% Chikungunya IgM+. STORCH screening in mother: 11.6% IgG + anti-Toxoplasma gondii, 6% IgG + anti-rubella, 4.7% IgG + CMV. The rest of STORCH tests were negative. Microcephaly was observed in 2.4% of the newborns. No calcifications or other CNS alterations were detected. One newborn had cleft palate and one had bilateral renal ectopy. CONCLUSIONS: The rate of microcephaly in our cohort was consistent with other studies. Pregnant women in endemic areas should be followed and tested according to standard protocols, and asymptomatic ZIKV infection should be considered. Long-term follow-up of children is required in the congenital Zika syndrome (CZS) assessment.
Authors: Ludmila Lobkowicz; Anna Ramond; Nuria Sanchez Clemente; Ricardo Arraes de Alencar Ximenes; Demócrito de Barros Miranda-Filho; Ulisses Ramos Montarroyos; Celina Maria Turchi Martelli; Thalia Velho Barreto de Araújo; Elizabeth B Brickley Journal: BMJ Glob Health Date: 2020-05
Authors: Monika B S Oliveira; Iara B Valentim; Tauane S Rocha; Jaqueline C Santos; Keyla S N Pires; Eloiza L L Tanabe; Karen S C Borbely; Alexandre U Borbely; Marília O F Goulart Journal: Ind Crops Prod Date: 2020-04-28 Impact factor: 5.645
Authors: Marlos Melo Martins; Antonio José Ledo Alves da Cunha; Jaqueline Rodrigues Robaina; Carlos Eduardo Raymundo; Arnaldo Prata Barbosa; Roberto de Andrade Medronho Journal: PLoS One Date: 2021-02-19 Impact factor: 3.240
Authors: Luxi Qiao; Celina M Turchi Martelli; Amber I Raja; Nuria Sanchez Clemente; Thalia Velho Barreto de Araùjo; Ricardo Arraes de Alencar Ximenes; Demócrito de Barros Miranda-Filho; Anna Ramond; Elizabeth B Brickley Journal: BMJ Glob Health Date: 2021-06